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Introduction
Coronavirus (COVID-19) is a respiratory tract infection 
caused by a newly emerging coronavirus, which was first 
identified in Wuhan, China, in December 2019. Genetic 
sequencing of this virus suggests that it is a beta-coronavi-
rus closely related to SARS virus [1]. The complete clinical 
picture is not yet well defined, as the reported symptoms 
range from asymptomatic and mild to severe cases, such as 
acute respiratory distress syndrome, septic or septic shock, 
and polyorganic failure, including acute kidney damage and 
cardiac, with a high risk of mortality in the elderly [2-5]. The 
elderly, especially those with comorbidities, are a group at 
high risk of death. In addition, a recent multivariate analysis 
confirmed that advanced age is the cause of sequential or-
ganic failure [1, 2]. 
While most people with COVID-19 develop only a mild 
or uncomplicated form, about 14% develop a serious ill-
ness that requires hospitalization and oxygen therapy, and 
5% require hospitalization in the intensive care unit [6]. 
Susceptibility is associated with age, sex, and comorbidi-
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Abstract
Background: The new SARS-CoV-2 coronavirus affects a large number of people worldwide, and the elderly are particularly affected because of their 
vulnerability. Thus, the elderly patients and those with comorbidities have an increased risk of developing a severe disease and show an increased 
mortality rate. Although they may show mild symptoms of illness and low-grade fever in the early days, they may worsen clinically rapidly, requiring 
ongoing monitoring. 
Material and methods: The prospective study was performed on a group of 96 patients (mean age 61.41 ± 3.42 years), with a predominance of men, 
hospitalized in the Holy Trinity Hospital of Chisinau who met the clinical case definition and were laboratory case-confirmed with COVID-19. Patients 
were clinically and paraclinically investigated according to the WHO Provisional National Clinical Protocol for COVID-19 infection reporting. The data 
were statistically processed by the Statistics 10 program. 
Results: Of the 96 patients with COVID-19, 85 (88.54%) reported at least one had a comorbidity. The prevalence of comorbidities was the following: 
chronic coronary syndromes (40.1%), hypertension (39.7%), diabetes (16.04%), chronic obstructive pulmonary disease (17.3%), malignancy (13.04%), 
cerebrovascular disease (10.6%), chronic kidney disease (4.3%) and viral hepatitis B (1.8%). Severe cases of the disease were revealed – 58, medium severity 
– 38 cases. All critical cases resulting in death (7.29%) showed comorbidities with respiratory symptoms, as well as with the onset of acute respiratory failure. 
Conclusions: The elderly, male gender and the presence of comorbidities in patients with COVID-19 determine the severe course of the disease and an 
increased mortality rate.
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ties [7, 8]. There are currently numerous studies on SARS-
CoV-2 and COVID-19. This review provides a comprehen-
sive introduction to this disease, including the structure of 
the genome and the SARS-CoV-2 receptor, epidemiology, 
clinical features, diagnosis, treatment, and prognosis of 
COVID-19. At present, research is needed to provide us 
with more information to understand this disease, to help 
limit the spread of the disease and to invent the vaccine and 
specific drugs [1].
COVID-19 infection begins as an infection of the local 
upper respiratory tract, which can spread to affect several 
organ systems with consequences that are only now under-
stood. When it spreads, it might result in a multisystem dis-
ease associated with a high risk of death. The clinical picture 
accompanied by manifestations from other organs and sys-
tems of COVID-19 infection is caused by a combination of 
specific host defense responses with associated inflammato-
ry activity and (micro) vascular involvement, with distinct 
coagulopathy and a strong propensity to develop thrombo-
embolic complications [3, 8]. The purpose of this paper was 
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to evaluate the evolutionary features of SARS-VOC-2 infec-
tion in elderly patients. 
Material and methods
The prospective study was performed on a group of 96 
patients (mean age 61.41 ± 3.42 years), with a predomi-
nance of men (men 59.3% vs 40.7% women) hospitalized in 
the Holy Trinity Municipal Hospital who had met the clini-
cal and laboratory case-confirmed definition of COVID-19. 
Patients were clinically and paraclinically investigated ac-
cording to the WHO Provisional National Clinical Protocol 
for COVID-19 infection reporting. The data were statisti-
cally processed via the Statistics 10 program. The informa-
tion was searched in PubMed, Springer, including the pages 
of the official websites of the European Geriatric Society, 
French, American and Italian National Geriatrics and 
Gerontology Societies, to identify scientific journals dedi-
cated to COVID-19. Sources published between December 
2019 and May 2020, in English and French, were selected, 
using the following keywords: “SARS CoV-2, COVID-19”, 
“clinical characteristics of older adult CoV-2”, “coronovirus 
impact”, and ”Elderly”.
Results
According to the results of the studies, the elderly show 
similar symptoms of SARS-CoV-2 compared to the younger 
people. The first manifestations in geriatric patients, related 
to COVID-19 disease reported by Nguyenau S. et al. were 
the worsening of the general condition, the decreased mo-
bility on the background of myalgias and the persistence 
of an overall weakness. Some clinical manifestations in the 
elderly, described by this group of authors may occur sepa-
rately or may even be preceded by a few days the appearance 
of respiratory symptoms or fever [9].
Symptoms of COVID-19 initially start with fatigue, pro-
longed low-grade fever, myalgia, dry cough, and difficulty 
breathing, which then improve with early identification, 
initiation and administration of conservative treatment, or 
worsen and progress to dyspnea and productive cough. In 
several studies, it was found that the average time for the 
onset of dyspnea in different cohorts was 6 days after ex-
posure. The most common complications that develop in 
COVID-19 are bilateral pneumonia that can progress to 
respiratory distress, sepsis and septic shock, acute kidney 
damage and others, such as acute heart damage (arrhyth-
mias, heart failure, MI), coagulopathy, rhabdomyolysis, 
hyponatremia and acidosis. Complications are more severe 
than non-severe diseases [1, 8, 9].
The main underlying co-morbidities that complicate 
the course of COVID-19 by increasing the disease sever-
ity, use of mechanical ventilation as well as length of stay, 
thus exhibiting  high risk of mortality include uncontrolled 
hypertension, diabetes, coronary heart disease, hepatitis B, 
cerebrovascular disease, chronic obstructive disease of the 
respiratory tract and other diseases, such as cancer, chronic 
kidney disease and immunodeficiency. Covid-19 has many 
clinical features similar to SARS. Although the symptoms 
are characterized as nonspecific, they often resemble flu 
even more than the common cold. Predominant symptoms 
include fever, cough and myalgia. Diarrhea and nausea may 
precede fever and respiratory symptoms. The elderly men 
and those with comorbidities have the highest risk of severe 
form (huang, chen). The milder form can resolve without 
medical care or can progress to pneumonia and respiratory 
failure that requires hospitalization. Patients can progress 
rapidly to respiratory distress with polyorganic dysfunction 
and insufficiency. Leukopenia and lymphopenia are fre-
quently detected [1, 10, 11].
The prospective study was performed on a group of 96 
patients (mean age 61.41 ± 3.42 years), hospitalized within 
the Holy Trinity Municipial Hospital. Of the 96 patients 
with COVID-19, 85 (88.54%) were reported to have at least 
one comorbidity. The prevalence of specific comorbidities 
were the following: chronic coronary syndromes (40.1%), 
hypertension (39.7%), diabetes (16.04%), chronic obstruc-
tive pulmonary disease (17.3%), malignancy (13.04 %), 
cerebrovascular disease (10.6%), chronic kidney disease 
(4.3%) and viral hepatitis B (1.8%) (fig. 1).
The stratification of patients according to the disease 
severity revealed severe cases in 58 patients (60.4%) of the 
studied subjects, medium severity – 38 (39.6%), whereas 
milder forms were not detected. Severe forms predominat-
ed in patients older than 65 years (mean age – 69.2 ± 4.42 
years), compared with moderate forms (mean age – 53.6 
± 3.12 years). All the critical cases resulting in death were 
registered in older patients (average: 80.33 vs 55.64 years) 
that made up 7.29% of cases with present comorbidities, in 
whom the respiratory symptoms worsened within a week 
with the onset of insufficiency acute respiratory and rapid 
progression of the lung CT scan.
Fig. 1. Prevalence of comorbidities in patients  
included in the study
Independent predictors of high mortality are the el-
derly (age ≥70 years); the underlying co-morbidities, such 
as uncontrolled hypertension, diabetes and coronary heart 
disease, chronic obstructive pulmonary disease and malig-
nancy; severe lymphopenia (<0.8 × 109 / L) and D-dimer 
(>1 μg / L) were reported [10]. Other prognostic factors are 
elevated C-reactive protein, HDL, ALT, serum ferritin, IL-6 
and high-sensitivity cardiac troponin.
Clinical manifestations of patients infected with SARS-
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CoV-2 ranged from mild nonspecific symptoms to severe 
pneumonia with impaired organ function. Common symp-
toms were fever (98.6%), cough (81.8%), fatigue (69.6%), 
dyspnea (55.0%), myalgia (34.8%), sputum production 
(56.5%) and headaches (33.9%). Sore throat, rhinorrhea, 
chest pain, hemoptysis, conjunctival congestion, diarrhea, 
nausea and vomiting were uncommon [6, 12, 13]
The elderly are more sensitive to COVID-19 and have a 
significantly increased risk of morbidity and mortality [11]. 
Infections are often atypical, sometimes confusing. The fac-
tors that contribute to this are the physiological changes of 
aging; multiple age-related comorbid conditions, such as 
cardiovascular and pulmonary pathology, diabetes and de-
mentia, as well as associated polypragmatism. Older adults 
living in care facilities have the highest risk due to chronic 
diseases and socio-economic impact. However, for all older 
adults, prevention is paramount [11].
Discussion
Timely recognition of the appropriate history of expo-
sure and prompt recognition of symptoms will help to early 
identify these cases and better track contacts for early iso-
lation. This will help reduce unwanted events and prevent 
the further spread of the infection; it will also help reduce 
COVID-19-related morbidity and mortality. Due to physi-
ological changes in aging, immune function decreases and 
the prevalence of multi-morbidity increases, especially 
in the elderly, who have a significantly increased risk of 
COVID-19 [1]. Older adults are more susceptible to the in-
fection itself and are more likely to suffer from the severe 
form of COVID-19 as well as its complications. Age chang-
es can also complicate the diagnosis in the elderly category 
with often atypically respiratory viruses present. The aver-
age duration from the onset of symptoms to death is 11.5 
days in people > 70 years vs 14 days in young people [5].
Coronaviruses are important pathogens in humans and 
animals that can cause diseases ranging from the common 
cold to more severe and even fatal respiratory infections. In 
the last two decades, two highly pathogenic human corona-
viruses, the coronavirus responsible for severe acute respira-
tory syndrome (SARS-Cov) and the coronavirus responsible 
for respiratory syndrome in the Middle East (MERS-Cov), 
12 have appeared as two separate events. They induced 
lower respiratory tract infections as well as extrapulmonary 
manifestations, leading to hundreds or thousands of cases 
with high mortality rates of up to 50% in some populations.
The comorbidities detected in the patients included in 
the study were hypertension, diabetes, cardiovascular pa-
thology, cerebrovascular disease, chronic renal disease, 
COPD, CVD, diabetes mellitus, malignancy, which correlat-
ed with the severity of the disease and the increased mortal-
ity rate in elderly patients [14-16]. It is noteworthy that the 
70-year-olds had a shorter time interval (11.5 days) between 
the first symptom and death than the younger subjects (20 
days), suggesting that the disease progressed faster in older 
adults [17].
Conclusions
The situation of the COVID-19 pandemic, the world is 
facing now is one of the most important geriatric emergen-
cies in 2020. The elderly are often asymptomatic or have 
atypical symptoms, often against an underlying physical 
and cognitive impairment, which are indicators of an un-
favorable prognosis. The old age, male gender and presence 
of comorbidities in patients with COVID-19 determine the 
severe course of the disease and its increased mortality.
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